We conducted a trial in which effective multimodal therapies without long-term castration were combined with the aim of achieving durable remission in patients with de novo oligometastatic prostate cancer.Here we report primary anal. results from SOLAR, a single-arm prospective phase 2 trial of primary tumor-directed therapy, metastasis-directed therapy (MDT), and intensified systemic therapy of limited duration conducted within the Veterans Affairs health care system.SOLAR enrolled patients with prostate adenocarcinoma, no prior treatment, testosterone >200 ng/dL, and M1a/b disease with one to five visible metastases on prostate-specific membrane antigen (PSMA), fluciclovine, or sodium fluoride (NaF) positron emission tomog./computed tomog. (PET/CT).Systemic therapy was limited to 6 mo and comprised s.c. leuprolide (45 mg), oral apalutamide (240 mg daily), and oral abiraterone acetate plus prednisone (AAP, 1000 mg/10 mg daily).Primary tumor-directed therapy was radical prostatectomy (RP) and lymph node dissection with selective postoperative radiotherapy (RT), or RT directed to the prostate, seminal vesicles, and pelvic lymph nodes.Time-to-event endpoints from initiation of systemic therapy were assessed via Kaplan-Meier anal. FACT-P scores were assessed as the change from baseline.All of the patients completed systemic therapy with at least leuprolide and AAP or apalutamide, and 62.5% completed all planned systemic therapy, and no grade > 2 toxicities were attributable to MDT.Therefore, a comprehensive treatment strategy that includes primary and MDT with limited-duration systemic therapy achieved lasting remissions without ongoing castration therapy for a majority of patients in this trial with de novo oligometastatic prostate cancer while maintaining QoL and recovered testosterone.